An estimate of the economic impact of immunotherapy relative to PD-L1 expression in Brazil - An update with brazilian costs

Aguiar, Pedro, Jr.; De Mello, Ramon Andrade; Tadokoro, Hakaru; Babiker, Hani; Lopes, Gilberto

http://hdl.handle.net/10400.1/13305

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
1-s2.0-S1556086416317361-main.pdf		92.06 KB	Adobe PDF	Download

Send Feedback

Authors

Aguiar, Pedro, Jr.

De Mello, Ramon Andrade

Tadokoro, Hakaru

Babiker, Hani

Lopes, Gilberto

Abstract(s)

Delivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers, especially in lowand middle-income countries. The objective of our study is to assess the economic impact of nivolumab and pembrolizumab with and without the use of PD-L1 as a biomarker in Brazil.